Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shrinking skin cancer before surgery: new drug shows promise

NCT ID NCT04154943

Completed Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested giving the drug cemiplimab before surgery to people with advanced skin cancer (stage II to IV). The goal was to see if the drug could shrink or eliminate the tumor before the operation. 79 adults took part. The main focus was on how many patients had no cancer cells left in the removed tissue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

  • Regeneron Study Site

    Palo Alto, California, 94304, United States

  • Regeneron Study Site

    Washington D.C., District of Columbia, 20037, United States

  • Regeneron Study Site

    Miami, Florida, 33176, United States

  • Regeneron Study Site

    Tampa, Florida, 33612, United States

  • Regeneron Study Site

    Baltimore, Maryland, 21231, United States

  • Regeneron Study Site

    Boston, Massachusetts, 02114, United States

  • Regeneron Study Site

    Boston, Massachusetts, 02215, United States

  • Regeneron Study Site

    Ann Arbor, Michigan, 48109, United States

  • Regeneron Study Site

    Omaha, Nebraska, 68114, United States

  • Regeneron Study Site

    New York, New York, 10065, United States

  • Regeneron Study Site

    Charlotte, North Carolina, 28204, United States

  • Regeneron Study Site

    Durham, North Carolina, 27710, United States

  • Regeneron Study Site

    Cleveland, Ohio, 44195, United States

  • Regeneron Study Site

    Dallas, Texas, 75390, United States

  • Regeneron Study Site

    Houston, Texas, 77030, United States

  • Regeneron Study Site

    St Leonards, New South Wales, 2065, Australia

  • Regeneron Study Site

    Herston, Queensland, 4029, Australia

  • Regeneron Study Site

    Melbourne, Victoria, 3000, Australia

  • Regeneron Study Site

    Dresden, 01307, Germany

  • Regeneron Study Site

    Essen, 45147, Germany

  • Regeneron Study Site

    Kiel, 24105, Germany

  • Regeneron Study Site

    Tübingen, 72076, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.